| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7534431 | Transfusion Clinique et Biologique | 2018 | 5 Pages |
Abstract
Improving the medical care of homozygous β-thalassemic children requires adherence to transfusion regimen and chelation therapy. Bone marrow transplantation remains the only possible curative therapy, which must be promoted in our country.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
I. Maaloul, O. Laaroussi, I. Jedidi, L. Sfaihi, S. Kmiha, T. Kamoun, H. Aloulou, M. Hachicha,